JOHN W. KOZARICH, PH.D. - Corporate Board Profile

LIGAND PHARMACEUTICALS INC

Filing Date	Source Excerpt
2018-04-30	John W. Kozarich, Ph.D. Chairman of the Board 2003 68; Member of the nominating and corporate governance committee; 2017 compensation total $291,078.
2019-04-24	John W. Kozarich, Ph.D. (N) 69 2003 Distinguished Scientist and Executive Advisor of ActivX Biosciences, Inc. ... Dr. Kozarich received 493 restricted stock units with a grant date fair value of $96,584 and 2,456 stock options with a grant date fair value of $186,596. Total: $363,365.
2020-04-24	John W. Kozarich, Ph.D. (N) 70 2003 Interim CEO of Curza Global, LLC ... Dr. Kozarich earned his B.S. in chemistry, summa cum laude, from Boston College, his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard. ... The nominating and corporate governance committee currently consists of Mr. Aryeh (chair) and Drs. Kozarich and Sabba. ... John W. Kozarich 85,027 94,848 190,025 369,900 ... (4) As of December 31, 2019, Dr. Kozarich held options to purchase 39,401 shares of our common stock and 835 restricted stock units. During 2019, Dr. Kozarich received 835 restricted stock units with a grant date fair value of $94,848 and 4,071 stock options with a grant date fair value of $190,025.
2021-04-23	John W. Kozarich, Ph.D., has served as a member of our board since March 2003. Since November 2019, Dr. Kozarich has served as interim Chief Executive Officer of Curza Global, LLC, a biopharmaceutical company, where he has served as a member of the board of directors since February 2019. Dr. Kozarich also serves as Distinguished Scientist Emeritus of ActivX Biosciences, Inc., and previously served as ActivX’s Chairman and President from 2004 through March 2017. From 1992 to 2001, Dr. Kozarich was vice president at Merck Research Laboratories and previously held professorships at the University of Maryland and Yale University School of Medicine. Dr. Kozarich is also an adjunct professor of Chemical Biology and Medicinal Chemistry at the University of Texas, Austin and serves on the board of Intec Pharma Ltd., a publicly-traded biotechnology company. Previously, Dr. Kozarich served as a director of ActivX Biosciences Inc., Corium Intl, Novelion Therapeutics and Retrophin, Inc. He is also a recipient of the Distinguished Scientist Award from the San Diego Section of the American Chemical Society. Dr. Kozarich earned his B.S. in chemistry, summa cum laude, from Boston College, his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard. In selecting Dr. Kozarich to serve as a director, the board considered, among other things, his valuable pharmaceutical and international experience, including his service at Merck Research Laboratories, which is part of one of the world’s largest pharmaceutical companies, and his service with ActivX Biosciences, Inc., Novelion Therapeutics Inc. and Corium Intl. Our company also benefits from Dr. Kozarich’s financial and accounting experience in the pharmaceutical and biotechnology industries.
2022-04-22	John W. Kozarich, Ph.D., has served as a member of our board since March 2003. Dr. Kozarich is interim CEO of Curza Global, LLC and Distinguished Scientist Emeritus of ActivX Biosciences, Inc. He is a member of the nominating and corporate governance committee. Total compensation for 2021 was $347,807.
2023-04-20	John W. Kozarich, Ph.D., has served as a member of the Board since March 2003. Since November 2021, Dr. Kozarich has been the CEO of Marsal Therapeutics. Dr. Kozarich also serves as the Chairman of board of Curza Global, LLC, a biopharmaceutical company, where he has been a member of the board of directors since February 2019. In addition, Dr. Kozarich serves as Distinguished Scientist Emeritus of ActivX Biosciences, Inc., and previously served as ActivX’s Chairman and President from 2004 through March 2017. From 1992 to 2001, Dr. Kozarich was Vice President at Merck Research Laboratories and previously held professorships at the University of Maryland and Yale University School of Medicine. Dr. Kozarich is also an adjunct professor of Chemical Biology and Medicinal Chemistry at the University of Texas, Austin and serves on the board of Intec Pharma Ltd., a publicly-traded biotechnology company. Previously, Dr. Kozarich served as a director of ActivX Biosciences Inc., Corium Intl, Novelion Therapeutics and Retrophin, Inc. He is also a recipient of the Distinguished Scientist Award from the San Diego Section of the American Chemical Society. Dr. Kozarich earned his B.S. in chemistry, summa cum laude, from Boston College, his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard. In selecting Dr. Kozarich to serve as a director, the Board considered, among other things, his valuable pharmaceutical and international experience, including his service at Merck Research Laboratories, which is part of one of the world’s largest pharmaceutical companies, and his service with ActivX Biosciences, Inc., Novelion Therapeutics Inc. and Corium Intl. Our company also benefits from Dr. Kozarich’s financial and accounting experience in the pharmaceutical and biotechnology industries.
2024-04-25	John W. Kozarich, Ph.D. (N) 74 2003 Chief Executive Officer of Marsal Therapeutics ... (A) Member of the audit committee (the “Audit Committee”). (HC) Member of the human capital management and compensation committee (the “Human Capital Management and Compensation Committee”). (N) Member of the nominating and corporate governance committee (the “Nominating and Corporate Governance Committee”). ... DIRECTOR COMPENSATION TABLE ... John W. Kozarich, Ph.D. 90,096 84,234 187,371 361,701 ... The Nominating and Corporate Governance Committee currently consists of Mr. Aryeh (Chair), Ms. Zimmermann and Drs. Gray and Kozarich.